APO Research
Talk to an analyst

APO RESEARCH · REPORT

Uterine Fibroid Embolization Agents

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Uterine Fibroid Embolization Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025182 pages

Choose your research edition.

Industry ResearchUterine Fibroid Embolization Agents Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Uterine Fibroid Embolization Agents Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Uterine Fibroid Embolization Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Uterine Fibroid Embolization Agents Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Uterine Fibroid Embolization Agents Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Uterine Fibroid Embolization Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Uterine Fibroid Embolization Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Uterine Fibroid Embolization Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Uterine Fibroid Embolization Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Uterine Fibroid Embolization Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Uterine Fibroid Embolization Agents include Pfizer, Boston Scientific Corporation, Nippon Kayaku, Merit Medical Systems, Cook Medical and Astellas Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Uterine Fibroid Embolization Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Uterine Fibroid Embolization Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Uterine Fibroid Embolization Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Uterine Fibroid Embolization Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Uterine Fibroid Embolization Agents Segment by Company

Pfizer

Boston Scientific Corporation

Nippon Kayaku

Merit Medical Systems

Cook Medical

Astellas Pharma

Uterine Fibroid Embolization Agents Segment by Type

Polymethyl Methacrylate (PMMA) Microspheres

Polyvinyl Alcohol (PVA) Particles

Gelatin Sponge

Trisacryl Gelatin Microspheres (TAGM)

Others

Uterine Fibroid Embolization Agents Segment by Application

Hospital

Surgical Centers

Clinical Research Institutes

Others

Uterine Fibroid Embolization Agents Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uterine Fibroid Embolization Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Uterine Fibroid Embolization Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uterine Fibroid Embolization Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Uterine Fibroid Embolization Agents market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Uterine Fibroid Embolization Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Uterine Fibroid Embolization Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Uterine Fibroid Embolization Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Uterine Fibroid Embolization Agents Industry Trends Table 2. Uterine Fibroid Embolization Agents Industry Drivers Table 3. Uterine Fibroid Embolization Agents Industry Opportunities and Challenges Table 4. Uterine Fibroid Embolization Agents Industry Restraints Table 5. Global Uterine Fibroid Embolization Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Uterine Fibroid Embolization Agents Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Uterine Fibroid Embolization Agents Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Uterine Fibroid Embolization Agents Sales Market Share by Manufacturers Table 9. Global Uterine Fibroid Embolization Agents Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Uterine Fibroid Embolization Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Uterine Fibroid Embolization Agents Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Uterine Fibroid Embolization Agents Manufacturers, Product Type & Application Table 13. Global Uterine Fibroid Embolization Agents Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Uterine Fibroid Embolization Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Polymethyl Methacrylate (PMMA) Microspheres Table 17. Major Manufacturers of Polyvinyl Alcohol (PVA) Particles Table 18. Major Manufacturers of Gelatin Sponge Table 19. Major Manufacturers of Trisacryl Gelatin Microspheres (TAGM) Table 20. Major Manufacturers of Others Table 21. Global Uterine Fibroid Embolization Agents Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Uterine Fibroid Embolization Agents Sales by Type (2021-2026) & (K Units) Table 23. Global Uterine Fibroid Embolization Agents Sales by Type (2027-2032) & (K Units) Table 24. Global Uterine Fibroid Embolization Agents Sales Market Share by Type (2021-2026) Table 25. Global Uterine Fibroid Embolization Agents Sales Market Share by Type (2027-2032) Table 26. Global Uterine Fibroid Embolization Agents Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Uterine Fibroid Embolization Agents Revenue by Type (2021-2026) & (K Units) Table 28. Global Uterine Fibroid Embolization Agents Revenue by Type (2027-2032) & (K Units) Table 29. Global Uterine Fibroid Embolization Agents Revenue Market Share by Type (2021-2026) Table 30. Global Uterine Fibroid Embolization Agents Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Surgical Centers Table 33. Major Manufacturers of Clinical Research Institutes Table 34. Major Manufacturers of Others Table 35. Global Uterine Fibroid Embolization Agents Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Uterine Fibroid Embolization Agents Sales by Application (2021-2026) & (K Units) Table 37. Global Uterine Fibroid Embolization Agents Sales by Application (2027-2032) & (K Units) Table 38. Global Uterine Fibroid Embolization Agents Sales Market Share by Application (2021-2026) Table 39. Global Uterine Fibroid Embolization Agents Sales Market Share by Application (2027-2032) Table 40. Global Uterine Fibroid Embolization Agents Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Uterine Fibroid Embolization Agents Revenue by Application (2021-2026) & (K Units) Table 42. Global Uterine Fibroid Embolization Agents Revenue by Application (2027-2032) & (K Units) Table 43. Global Uterine Fibroid Embolization Agents Revenue Market Share by Application (2021-2026) Table 44. Global Uterine Fibroid Embolization Agents Revenue Market Share by Application (2027-2032) Table 45. Global Uterine Fibroid Embolization Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Uterine Fibroid Embolization Agents Sales by Region (2021-2026) & (K Units) Table 47. Global Uterine Fibroid Embolization Agents Sales Market Share by Region (2021-2026) Table 48. Global Uterine Fibroid Embolization Agents Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Uterine Fibroid Embolization Agents Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Uterine Fibroid Embolization Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 52. North America Uterine Fibroid Embolization Agents Sales by Country (2027-2032) & (K Units) Table 53. Europe Uterine Fibroid Embolization Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 55. Europe Uterine Fibroid Embolization Agents Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Uterine Fibroid Embolization Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Uterine Fibroid Embolization Agents Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Uterine Fibroid Embolization Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country (2027-2032) & (K Units) Table 62. Global Uterine Fibroid Embolization Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Uterine Fibroid Embolization Agents Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Uterine Fibroid Embolization Agents Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Uterine Fibroid Embolization Agents Revenue Market Share by Region (2021-2026) Table 66. Global Uterine Fibroid Embolization Agents Revenue Market Share by Region (2027-2032) Table 67. Pfizer Company Information Table 68. Pfizer Business Overview Table 69. Pfizer Uterine Fibroid Embolization Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Pfizer Uterine Fibroid Embolization Agents Product Portfolio Table 71. Pfizer Recent Development Table 72. Boston Scientific Corporation Company Information Table 73. Boston Scientific Corporation Business Overview Table 74. Boston Scientific Corporation Uterine Fibroid Embolization Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Boston Scientific Corporation Uterine Fibroid Embolization Agents Product Portfolio Table 76. Boston Scientific Corporation Recent Development Table 77. Nippon Kayaku Company Information Table 78. Nippon Kayaku Business Overview Table 79. Nippon Kayaku Uterine Fibroid Embolization Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Nippon Kayaku Uterine Fibroid Embolization Agents Product Portfolio Table 81. Nippon Kayaku Recent Development Table 82. Merit Medical Systems Company Information Table 83. Merit Medical Systems Business Overview Table 84. Merit Medical Systems Uterine Fibroid Embolization Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Merit Medical Systems Uterine Fibroid Embolization Agents Product Portfolio Table 86. Merit Medical Systems Recent Development Table 87. Cook Medical Company Information Table 88. Cook Medical Business Overview Table 89. Cook Medical Uterine Fibroid Embolization Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Cook Medical Uterine Fibroid Embolization Agents Product Portfolio Table 91. Cook Medical Recent Development Table 92. Astellas Pharma Company Information Table 93. Astellas Pharma Business Overview Table 94. Astellas Pharma Uterine Fibroid Embolization Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Astellas Pharma Uterine Fibroid Embolization Agents Product Portfolio Table 96. Astellas Pharma Recent Development Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Uterine Fibroid Embolization Agents Distributors List Table 100. Uterine Fibroid Embolization Agents Customers List Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Uterine Fibroid Embolization Agents Product Image Figure 2. Global Uterine Fibroid Embolization Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Uterine Fibroid Embolization Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Uterine Fibroid Embolization Agents Sales (2021-2032) & (K Units) Figure 5. Global Uterine Fibroid Embolization Agents Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Uterine Fibroid Embolization Agents Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Polymethyl Methacrylate (PMMA) Microspheres Image Figure 9. Polyvinyl Alcohol (PVA) Particles Image Figure 10. Gelatin Sponge Image Figure 11. Trisacryl Gelatin Microspheres (TAGM) Image Figure 12. Others Image Figure 13. Global Uterine Fibroid Embolization Agents Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Uterine Fibroid Embolization Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Uterine Fibroid Embolization Agents Sales Market Share by Type (2021-2032) Figure 16. Global Uterine Fibroid Embolization Agents Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Uterine Fibroid Embolization Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Uterine Fibroid Embolization Agents Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Surgical Centers Image Figure 21. Clinical Research Institutes Image Figure 22. Others Image Figure 23. Global Uterine Fibroid Embolization Agents Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Uterine Fibroid Embolization Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Uterine Fibroid Embolization Agents Sales Market Share by Application (2021-2032) Figure 26. Global Uterine Fibroid Embolization Agents Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Uterine Fibroid Embolization Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Uterine Fibroid Embolization Agents Revenue Market Share by Application (2021-2032) Figure 29. North America Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2032) Figure 31. U.S. Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2032) Figure 36. Germany Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2032) Figure 43. China Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Uterine Fibroid Embolization Agents Sales Market Share by Country (2021-2032) Figure 51. Brazil Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Uterine Fibroid Embolization Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Uterine Fibroid Embolization Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Uterine Fibroid Embolization Agents Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Uterine Fibroid Embolization Agents Revenue (2021-2032) & (US$ Million) Figure 62. North America Uterine Fibroid Embolization Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Uterine Fibroid Embolization Agents Revenue (2021-2032) & (US$ Million) Figure 64. Europe Uterine Fibroid Embolization Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Uterine Fibroid Embolization Agents Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Uterine Fibroid Embolization Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Uterine Fibroid Embolization Agents Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Uterine Fibroid Embolization Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Uterine Fibroid Embolization Agents Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Uterine Fibroid Embolization Agents Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Polymethyl Methacrylate (PMMA) Microspheres
  • Polyvinyl Alcohol (PVA) Particles
  • Gelatin Sponge
  • Trisacryl Gelatin Microspheres (TAGM)
  • Others
Applications
  • Hospital
  • Surgical Centers
  • Clinical Research Institutes
  • Others
Companies covered
  • Pfizer
  • Boston Scientific Corporation
  • Nippon Kayaku
  • Merit Medical Systems
  • Cook Medical
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Uterine Fibroid Embolization Agents Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Uterine Fibroid Embolization Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Uterine Fibroid Embolization Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Uterine Fibroid Embolization Agents Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Uterine Fibroid Embolization Agents Market Dynamics
  1. 2.1 Uterine Fibroid Embolization Agents Industry Trends
  2. 2.2 Uterine Fibroid Embolization Agents Industry Drivers
  3. 2.3 Uterine Fibroid Embolization Agents Industry Opportunities and Challenges
  4. 2.4 Uterine Fibroid Embolization Agents Industry Restraints
3 Uterine Fibroid Embolization Agents Market by Manufacturers
  1. 3.1 Global Uterine Fibroid Embolization Agents Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Uterine Fibroid Embolization Agents Sales by Manufacturers (2021-2026)
  3. 3.3 Global Uterine Fibroid Embolization Agents Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Uterine Fibroid Embolization Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Uterine Fibroid Embolization Agents Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Uterine Fibroid Embolization Agents Manufacturers, Product Type & Application
  7. 3.7 Global Uterine Fibroid Embolization Agents Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Uterine Fibroid Embolization Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Uterine Fibroid Embolization Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Uterine Fibroid Embolization Agents Tier 1, Tier 2, and Tier 3
4 Uterine Fibroid Embolization Agents Market by Type
  1. 4.1 Uterine Fibroid Embolization Agents Type Introduction
  2. 4.1.1 Polymethyl Methacrylate (PMMA) Microspheres
  3. 4.1.2 Polyvinyl Alcohol (PVA) Particles
  4. 4.1.3 Gelatin Sponge
  5. 4.1.4 Trisacryl Gelatin Microspheres (TAGM)
  6. 4.1.5 Others
  7. 4.2 Global Uterine Fibroid Embolization Agents Sales by Type
  8. 4.2.1 Global Uterine Fibroid Embolization Agents Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Uterine Fibroid Embolization Agents Sales by Type (2021-2032)
  10. 4.2.3 Global Uterine Fibroid Embolization Agents Sales Market Share by Type (2021-2032)
  11. 4.3 Global Uterine Fibroid Embolization Agents Revenue by Type
  12. 4.3.1 Global Uterine Fibroid Embolization Agents Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Uterine Fibroid Embolization Agents Revenue by Type (2021-2032)
  14. 4.3.3 Global Uterine Fibroid Embolization Agents Revenue Market Share by Type (2021-2032)
5 Uterine Fibroid Embolization Agents Market by Application
  1. 5.1 Uterine Fibroid Embolization Agents Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Surgical Centers
  4. 5.1.3 Clinical Research Institutes
  5. 5.1.4 Others
  6. 5.2 Global Uterine Fibroid Embolization Agents Sales by Application
  7. 5.2.1 Global Uterine Fibroid Embolization Agents Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Uterine Fibroid Embolization Agents Sales by Application (2021-2032)
  9. 5.2.3 Global Uterine Fibroid Embolization Agents Sales Market Share by Application (2021-2032)
  10. 5.3 Global Uterine Fibroid Embolization Agents Revenue by Application
  11. 5.3.1 Global Uterine Fibroid Embolization Agents Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Uterine Fibroid Embolization Agents Revenue by Application (2021-2032)
  13. 5.3.3 Global Uterine Fibroid Embolization Agents Revenue Market Share by Application (2021-2032)
6 Global Uterine Fibroid Embolization Agents Sales by Region
  1. 6.1 Global Uterine Fibroid Embolization Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Uterine Fibroid Embolization Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Uterine Fibroid Embolization Agents Sales by Region (2021-2026)
  4. 6.2.2 Global Uterine Fibroid Embolization Agents Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Uterine Fibroid Embolization Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Uterine Fibroid Embolization Agents Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Uterine Fibroid Embolization Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Uterine Fibroid Embolization Agents Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Uterine Fibroid Embolization Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Uterine Fibroid Embolization Agents Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Uterine Fibroid Embolization Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Uterine Fibroid Embolization Agents Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Uterine Fibroid Embolization Agents Revenue by Region
  1. 7.1 Global Uterine Fibroid Embolization Agents Revenue by Region
  2. 7.1.1 Global Uterine Fibroid Embolization Agents Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Uterine Fibroid Embolization Agents Revenue by Region (2021-2026)
  4. 7.1.3 Global Uterine Fibroid Embolization Agents Revenue by Region (2027-2032)
  5. 7.1.4 Global Uterine Fibroid Embolization Agents Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Uterine Fibroid Embolization Agents Revenue (2021-2032)
  8. 7.2.2 North America Uterine Fibroid Embolization Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Uterine Fibroid Embolization Agents Revenue (2021-2032)
  11. 7.3.2 Europe Uterine Fibroid Embolization Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Uterine Fibroid Embolization Agents Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Uterine Fibroid Embolization Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Uterine Fibroid Embolization Agents Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Uterine Fibroid Embolization Agents Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Uterine Fibroid Embolization Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Uterine Fibroid Embolization Agents Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Boston Scientific Corporation
  8. 8.2.1 Boston Scientific Corporation Company Information
  9. 8.2.2 Boston Scientific Corporation Business Overview
  10. 8.2.3 Boston Scientific Corporation Uterine Fibroid Embolization Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boston Scientific Corporation Uterine Fibroid Embolization Agents Product Portfolio
  12. 8.2.5 Boston Scientific Corporation Recent Developments
  13. 8.3 Nippon Kayaku
  14. 8.3.1 Nippon Kayaku Company Information
  15. 8.3.2 Nippon Kayaku Business Overview
  16. 8.3.3 Nippon Kayaku Uterine Fibroid Embolization Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Nippon Kayaku Uterine Fibroid Embolization Agents Product Portfolio
  18. 8.3.5 Nippon Kayaku Recent Developments
  19. 8.4 Merit Medical Systems
  20. 8.4.1 Merit Medical Systems Company Information
  21. 8.4.2 Merit Medical Systems Business Overview
  22. 8.4.3 Merit Medical Systems Uterine Fibroid Embolization Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merit Medical Systems Uterine Fibroid Embolization Agents Product Portfolio
  24. 8.4.5 Merit Medical Systems Recent Developments
  25. 8.5 Cook Medical
  26. 8.5.1 Cook Medical Company Information
  27. 8.5.2 Cook Medical Business Overview
  28. 8.5.3 Cook Medical Uterine Fibroid Embolization Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cook Medical Uterine Fibroid Embolization Agents Product Portfolio
  30. 8.5.5 Cook Medical Recent Developments
  31. 8.6 Astellas Pharma
  32. 8.6.1 Astellas Pharma Company Information
  33. 8.6.2 Astellas Pharma Business Overview
  34. 8.6.3 Astellas Pharma Uterine Fibroid Embolization Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Astellas Pharma Uterine Fibroid Embolization Agents Product Portfolio
  36. 8.6.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Uterine Fibroid Embolization Agents Value Chain Analysis
  2. 9.1.1 Uterine Fibroid Embolization Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Uterine Fibroid Embolization Agents Production Mode & Process
  6. 9.2 Uterine Fibroid Embolization Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Uterine Fibroid Embolization Agents Distributors
  9. 9.2.3 Uterine Fibroid Embolization Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst